68Ga-NI-FAPI PET/CT: First-in-human Study in Patients With Various Cancers
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Various solid tumors with available histopathological findings
• Signed informed consent
Locations
Other Locations
China
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITING
Fuzhou
Contact Information
Primary
Weibing Miao, MD
miaoweibing@126.com
+86-0591-87981618
Backup
Jie Zang, MD
15901495106@163.com
+86-0591-87981619
Time Frame
Start Date: 2024-08-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 40
Treatments
Experimental: 68Ga-NI-FAPI PET/CT
PET/CT imaging in patients with malignant tumors: each patient underwent a PET/CT scan after intravenous administration of 68Ga-NI-FAPI.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Fujian Medical University